TRULANCE

PeakPeptide

plecanatide

NDAORALTABLET
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
11

Mechanism of Action

Guanylate Cyclase Activators

Pharmacologic Class:

Guanylate Cyclase-C Agonist

Clinical Trials (5)

NCT03596905Phase 2Completed

Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bowel Syndrome With Constipation (IBS-C)

Started Jun 2018
NCT03551873N/ACompleted

A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE®

Started Jun 2018
NCT03120520Phase 2Completed

An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation

Started Jan 2017
NCT02706483Phase 3Completed

Long Term Safety Study of Plecanatide

Started Jan 2016
NCT02493452Phase 3Completed

Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)

Started Jun 2015

Loss of Exclusivity

LOE Date
Jun 5, 2034
100 months away
Patent Expiry
Jun 5, 2034

Patent Records (5)

Patent #ExpiryTypeUse Code
7041786
Jan 30, 2028
Substance
9925231
Sep 15, 2031
Product
9610321
Sep 15, 2031
U-2230
9919024
Sep 15, 2031
U-1999
11319346
Mar 1, 2032
Product